Denetclaw Tina Harrach, Yu Mark Kevin, Moua Mee, Dowling Thomas C, Steinke Douglas
Marin General Hospital, Greenbrae, CA, USA University of California, San Francisco, CA, USA
University of California, San Francisco, CA, USA.
Ann Pharmacother. 2015 Aug;49(8):861-8. doi: 10.1177/1060028015586423. Epub 2015 May 18.
Current guidelines recommend vancomycin trough concentrations of 15 to 20 µg/mL in complicated infections and all trough concentrations >10 µg/mL to avoid developing microbial resistance. To date, no published protocol reliably meets these recommendations for obese patients.
We assessed the performance of a novel, obese-specific, divided-load vancomycin protocol for attaining target trough concentrations within 12 to 24 hours of dosing initiation, and during maintenance dosing, in obese patients.
The protocol was evaluated through prospective medical record review in 54 consecutive obese patients. Vancomycin serum concentrations were drawn before the third and fifth dose after initiation. Steady-state concentrations were drawn after the third dose once maintenance dosing was achieved and periodically thereafter.
Within 12 hours after dosing initiation, 48 (89%) study patients exhibited trough concentrations of 10 to 20 µg/mL averaging 14.5 ± 3.2 µg/mL; 51 (94%) study patients exhibited trough concentrations >10 µg/mL within 12 hours after dosing initiation, and 3 (6%) had trough concentrations >20 µg/mL. Thirty-one participants had second trough concentrations drawn within 24 hours of dosing initiation, averaging 15.0 ± 3.1 µg/mL; 24 patients had a total of 32 trough concentrations drawn during maintenance dosing, averaging 15.1 ± 2.5 µg/mL.
Obese-specific, divided-load dosing achieved trough concentrations of 10 to 20 µg/mL for 89% of obese patients within 12 hours of initial dosing and 97% of obese patients within 24 hours of initial dosing while preventing doses given during supratherapeutic trough levels; 97% of troughs measured during steady state were within target range.
当前指南建议,在复杂感染中万古霉素谷浓度为15至20μg/mL,所有谷浓度>10μg/mL以避免产生微生物耐药性。迄今为止,尚无已发表的方案能可靠地满足肥胖患者的这些建议。
我们评估了一种新型的、针对肥胖患者的分剂量万古霉素方案在肥胖患者给药开始后12至24小时内以及维持给药期间达到目标谷浓度的效果。
通过对54例连续肥胖患者的前瞻性病历回顾来评估该方案。在开始给药后的第三剂和第五剂之前采集万古霉素血清浓度。达到维持给药后,在第三剂后采集稳态浓度,并在此后定期采集。
给药开始后12小时内,48例(89%)研究患者的谷浓度为10至20μg/mL,平均为14.5±3.2μg/mL;51例(94%)研究患者在给药开始后12小时内谷浓度>10μg/mL,3例(6%)谷浓度>20μg/mL。31名参与者在给药开始后24小时内进行了第二次谷浓度检测,平均为15.0±3.1μg/mL;24例患者在维持给药期间共进行了32次谷浓度检测,平均为15.1±2.5μg/mL。
针对肥胖患者的分剂量给药在初始给药后12小时内使89%的肥胖患者谷浓度达到10至20μg/mL,在初始给药后24小时内使97%的肥胖患者达到该浓度,同时防止了在治疗浓度以上的谷水平期间给药;稳态期间测量的97%的谷浓度在目标范围内。